Plain-English translation of NCT06651151 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medicines—LTX-315 and pembrolizumab—given before surgery in people with advanced melanoma that doctors believe can be completely removed. LTX-315 is injected directly into the tumor to help kill cancer cells and boost the immune system, while pembrolizumab is an infusion that helps your body's own immune cells fight the cancer. The goal is to see whether giving these medicines before surgery—rather than after—works better to prevent the cancer from coming back.
Pembrolizumab alone, given before surgery, only works completely in about 1 in 5 patients, and some patients' cancers get worse during treatment, making surgery no longer possible. Researchers believe that combining this medication with LTX-315 might improve how well the treatment works and prevent disease progression.
You likely qualify if…
You likely don't qualify if…
You will receive weekly injections of the medication directly into your tumor for up to 5 weeks, combined with infusions of the second medication every 3 weeks over about 9 weeks before your planned surgery. During this time, you'll have regular appointments for blood tests, scans, and biopsies to monitor how the treatment is working. After your surgery, you'll continue receiving the infusion medication for an additional period. The entire study involvement lasts several months, with follow-up visits to monitor for recurrence.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
Norway